Novalinko Bio Inc. is an antiviral and precision oncology company advancing next-generation therapeutics. By harnessing computer-aided drug design (CADD), we accelerate drug discovery, translating computationally identified targets into experimentally validated therapeutics.
Non-small cell lung cancer (NSCLC) and related malignancies. Our lead programs target high-unmet-need respiratory oncologies with computationally optimized mechanisms.
Gastric, colorectal, and other GI malignancies. Leveraging proprietary target identification to address treatment-resistant GI tumors.
Clinically validated targets with clear development pathways. Programs advancing from dry-lab validation to in vitro confirmation.